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Abstract
Noncompliance and missing data often occur in randomized trials, which complicate the infer-
ence of causal effects. When both noncompliance and missing data are present, previous papers
proposed moment and maximum likelihood estimators for binary and normally distributed contin-
uous outcomes under the latent ignorable missing data mechanism. However, the latent ignorable
missing data mechanism may be violated in practice, because the missing data mechanism may
depend directly on the missing outcome itself. Under noncompliance and an outcome-dependent
nonignorable missing data mechanism, previous studies showed the identifiability of complier av-
erage causal effect for discrete outcomes. In this paper, we study the semiparametric identifiability
and estimation of complier average causal effect in randomized clinical trials with both all-or-
none noncompliance and the outcome-dependent nonignorable missing continuous outcomes, and
propose a two-step maximum likelihood estimator in order to eliminate the infinite dimensional
nuisance parameter. Our method does not need to specify a parametric form for the missing data
mechanism. We also evaluate the finite sample property of our method via extensive simulation
studies and sensitivity analysis, with an application to a double-blinded psychiatric clinical trial.
Key Words: Causal inference; Instrumental variable; Missing not at random; Noncompliance;
Outcome-dependent missing; Principal stratification.
1 Introduction
Randomization is an effective way to study the average causal effects (ACEs) of new drugs or training
programs. However, randomized trials are often plagued with noncompliance and missing data, which
may make statistical inference difficult and biased. The noncompliance problem happens when some
subjects fail to comply with their assigned treatments, and the missing data problem happens when
investigators fail to collect information for some subjects. Ignoring noncompliance and missing data
problems may lead to biased estimators of the ACEs.
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The noncompliance problem has attracted a lot of attention in the literature. Efron and Feldman
(1991) studied the noncompliance problem before the principal stratification framework (Frangakis
and Rubin, 2002) was proposed. In the presence of noncompliance, Balke and Pearl (1997) pro-
posed large sample bounds of the ACEs for binary outcomes using the linear programming method.
Angrist et al. (1996) discussed the identifiability of the causal effect using the instrumental variable
method. Imbens and Rubin (1997) proposed a Bayesian method to estimate the complier average
causal effect (CACE). When some outcomes are missing, the identifiability and estimation of CACE
are more complicated, and different types of missing data mechanisms have sizable impacts on the
identifiability and estimation of CACE. Frangakis and Rubin (1999) established the identifiability and
proposed a moment estimator of CACE under the latent ignorable (LI) missing data mechanism. Un-
der the LI missing data mechanism, Zhou and Li (2006) and O’Malley and Normand (2005) proposed
Expectation-Maximization (EM) algorithms (Dempster et al., 1977) to find the maximum likelihood
estimators (MLEs) of CACE for binary and normally distributed outcomes, respectively. Barnard et al.
(2003) proposed a Bayesian approach to estimate CACE with bivariate outcomes and covariate adjust-
ment. Taylor and Zhou (2011) proposed a multiple imputation method to estimate CACE for clustered
encouragement design studies.
However, the LI assumption may be implausible in some clinical studies when the missing data
mechanism may depend on the missing outcome. Chen et al. (2009) and Imai (2009) discussed the
identifiability of CACE for discrete outcomes under the outcome-dependent nonignorable (ODN)
missing data mechanism. To the best of our knowledge, there are no published papers in the liter-
ature studying the identifiability of CACE for continuous outcomes under the ODN assumption. In
this paper, we show that CACE is semiparametrically identifiable under some regular conditions, and
propose estimation methods for CACE with continuous outcomes under the ODN assumption. For
our semiparametric method, we need only assume that the distribution of the outcomes belongs to the
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exponential family without specifying a parametric form for the missing data mechanism.
This paper proceeds as follows. In Section 2, we discuss the notation and assumptions used in this
paper and define the parameter of interest. In Section 3, we show the semiparametric identifiability and
propose a two-step maximum likelihood estimator (TSMLE). In Section 4, we use several simulation
studies to illustrate the finite sample properties of our proposed estimators and consider sensitivity
analysis to assess the robustness of our estimation strategy. In Section 5, we analyze a double-blinded
randomized clinical trial using the methods proposed in this paper. We conclude with a discussion and
provide all proofs in the Appendices.
2 Notation and Assumptions
We consider a randomized trial with a continuous outcome. For the i-th subject, let Zi denote the
randomized treatment assignment (1 for treatment and 0 for control). Let Di denote the treatment
received (1 for treatment and 0 for control). When Zi 6= Di, there exists noncompliance. Let Yi denote
the outcome variable. Let Ri denote the missing data indicator of Yi, i.e., Ri = 1 if Yi is observed and
Ri = 0 if Yi is missing. First, we need to make the following fundamental assumption.
Assumption 1 (Stable unit treatment value assumption, SUTVA): There is no interference between
units, which means that the potential outcomes of one individual do not depend on the treatment
status of other individuals (Rubin, 1980), and there is only one version of potential outcome of
a certain treatment (Rubin, 1986).
Except in the dependent case for infectious diseases (Hudgens and Halloran, 2008), the SUTVA as-
sumption is reasonable in many cases. Under the SUTVA assumption, we define Di(z),Yi(z) and Ri(z)
as the potential treatment received, the potential outcome measured, and the potential missing data
indicator for subject i if he/she were assigned to treatment z. These variables are potential outcomes
because only one of the pairs {Di(1),Yi(1),Ri(1)} and {Di(0),Yi(0),Ri(0)} can be observed. Since
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Zi is the observed treatment assignment for subject i, Di = Di(Zi),Yi = Yi(Zi), and Ri = Ri(Zi) are the
observed treatment received, the observed outcome, and the observed missing data indicator.
Under the principal stratification framework (Angrist et al., 1996; Frangakis and Rubin, 2002), we
let Ui be the compliance status of subject i, defined as follows:
Ui =

a, if Di(1) = 1 and Di(0) = 1;
c, if Di(1) = 1 and Di(0) = 0;
d, if Di(1) = 0 and Di(0) = 1;
n, if Di(1) = 0 and Di(0) = 0;
where a,c,d and n represent “always-taker”, “complier”, “defier” and “never-taker”, respectively.
Here Ui is an unobserved variable, because we can observe only Di(1) or Di(0) for subject i, but not
both. The CACE of Z to Y is the parameter of interest, defined as
CACE(Z→ Y ) = E{Y (1)−Y (0) |U = c}.
CACE is a subgroup causal effect for the compliers, with incompletely observed compliance status.
Next, we give some sufficient conditions about the latent variables to make CACE(Z→Y ) identifiable,
in the presence of noncompliance and nonignorable missing outcomes.
Assumption 2 (Randomization): The treatment assignment Z is completely randomized.
Randomization means that Z is independent of {D(1),D(0),Y (1),Y (0),R(1),R(0)}, and we define
ξ = P{Z = 1 | D(1),D(0),Y (1),Y (0),R(1),R(0)}= P(Z = 1). Under the randomization assumption,
CACE(Z→ Y ) can be expressed as
CACE(Z→ Y ) = E(Y | Z = 1,U = c)−E(Y | Z = 0,U = c).
Assumption 3 (Monotonicity): Di(1)≥ Di(0) for each subject i.
The monotonicity of Di(z) implies that there are no defiers. Define ωu =P(U = u) for u= a,c,d,n,
and the monotonicity assumption implies ωd = 0. Assumption 3 is plausible when the treatment as-
signment has a nonnegative effect on the treatment received for each subject, and it holds directly when
4
the treatment is not available to subjects in the control arm, meaning Di(0) = 0 for all subjects. The
monotonicity assumption implies a positive ACE of Z on D. However, under general circumstances,
Assumption 3 is not fully testable, since only one of Di(1) and Di(0) can be observed.
Assumption 4: ACE(Z→ D) 6= 0.
By randomization, we have that ACE(Z → D) = P(D = 1 | Z = 1)−P(D = 1 | Z = 0) 6= 0 under
Assumption 4, and therefore Z is correlated with D. Without Assumption 4, we have P(D = 1 | Z =
1) = P(D = 1 | Z = 0), which implies that ωc = 0 under Assumption 3. Since we are interested in the
identifiability of CACE(Z→ Y ), Assumption 4 is necessary.
Assumption 5 (Compound exclusion restrictions): For never-takers and always-takers, we assume
P{Y (1),R(1) |U = n} = P{Y (0),R(0) |U = n}, and P{Y (1),R(1) |U = a} = P{Y (0),R(0) |
U = a}.
The traditional exclusion restriction assumes P{Y (1) |U = u} = P{Y (0) |U = u} for u = a and
n. Frangakis and Rubin (1999) extended it to the compound exclusion restrictions, and imposed
similar assumption on the joint vector of the outcome and the missing data indicator. Assumption 5 is
reasonable in a double-blinded clinical trial, because the patients do not know the treatment assigned to
them and thus Z has no “direct effect” on the outcome and the missing data indicator. However, when
the missing data indicator depends on the treatment assigned, the compound exclusion restrictions
may be violated. When Z is randomized, Assumption 5 is equivalent to P(Y,R | Z = 1,U = n) =
P(Y,R | Z = 0,U = n) and P(Y,R | Z = 1,U = a) = P(Y,R | Z = 0,U = a).
Assumption 6 (Outcome-dependent nonignorable missing data): For all y; z = 0,1; d = 0,1; and
u ∈ {a,c,n}, we assume
P{R(z) = 1 | Y (z) = y,D(z) = d,U = u} = P{R(z) = 1 | Y (z) = y} (1)
P{R(1) = 1 | Y (1) = y} = P{R(0) = 1 | Y (0) = y}. (2)
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When Z is randomized, the equation (1) becomes P(R = 1 | Y = y,D = d,U = u,Z = z) = P(R = 1 |
Y = y,Z = z), and (2) becomes P(R = 1 | Y = y,Z = 1) = P(R = 1 | Y = y,Z = 0). Define ρ(y) =
P(R = 1 |Y = y). Therefore Assumption 2 and Assumption 6 imply that ρ(y) = P(R = 1 |Y = y,D =
d,U = u,Z = z). Hence R depends on Y , but is independent of (Z,D,U) given Y .
In previous papers (Frangakis and Rubin, 1999; O’Malley and Normand, 2005; Zhou and Li,
2006), the LI assumption is used for modeling missing data, which means that the potential outcomes
and associated potential nonresponse indicators are independent within each principal stratum, that is
P{R(z) | Y (z),D(z),U} = P{R(z) |U}. Under the ODN missing data mechanism, the missing data
indicator depends on the possibly missing outcome Y , which may be more reasonable than the LI
missing data assumption in some applications. For example, some patients may have higher probabil-
ities to leave the trial if their health outcomes are not good, and they may be more likely to stay in the
trial otherwise. We illustrate the LI and ODN missing data mechanisms using the graphical models in
Figure 1. Note that the arrows from Z to R are absent because of the compound exclusion restriction
assumption.
U
 

Z // D

// Y
R
U
 
Z // D // Y

R
(a) LI under Assumptions 2 and 5 (b) ODN under Assumptions 2 and 5
Figure 1: Graphical models for different missing data mechanisms
3 Semiparametric Identifiability and Estimation
In this section, we first discuss the difficulty of nonparametric identifiability without assuming a para-
metric form for both the outcome distribution and the missing data mechanism. If both the distribution
of the outcome Y and the missing data mechanism ρ(y) are not specified, the model is essentially not
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identifiable without further assumptions. We then propose a semiparametric method, specifying only
the distribution of Y without assuming any parametric form for the missing data mechanism. We show
the identifiability and propose a TSMLE of CACE(Z→ Y ) under the assumption that the distribution
of the outcome variable Y belongs to the exponential family.
3.1 Semiparametric Identifiability
Under SUTVA, randomization and monotonicity assumptions, we have ξ = P(Z = 1), ωa = P(U =
a) = P(D = 1 | Z = 0), ωn = P(U = n) = P(D = 0 | Z = 1), and ωc = 1−ωa−ωn. These parameters
can be identified directly from the observed data. Next we focus on the identification of the parameters
of Y .
Assumption 7: The conditional density of the outcome variable Y belongs to the following exponen-
tial family:
fzu(y) = f (y | Z = z,U = u) = c(θzu)h(y)exp
{
K
∑
k=1
pk(θzu)Tk(y)
}
, (3)
where c(·),h(·), pk(·), and Tk(·) are known functions, and θ = {θzu : z = 0,1;u = c,a,n} are
unknown parameters. We denote f (y | Z = z,U = u) simply as fzu hereinafter.
The parametric assumption of the outcome is untestable in general, since the missing data mecha-
nism depends arbitrarily on the outcome. But for binary outcome, Small and Cheng (2009) proposed a
goodness-of-fit test for the model under the ODN missing data mechanism. When the randomization
assumption holds, the CACE is the difference between the expectations of the conditional density of
Y , that is
CACE = E(Y | Z = 1,U = c)−E(Y | Z = 0,U = c) =
∫
y f1c(y)dy−
∫
y f0c(y)dy.
Hence if the parameters of fzu(y) are identified, the CACE is also identified. The exponential family de-
fined by Assumption 7 includes many common distributions, such as normal distributions N(µzu,σ2),
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exponential distributions Exp(λzu) with mean parameter 1/λzu, Gamma distributions Gamma(αzu,λ )
with shape parameter αzu and rate parameter λ , and the log-normal distributions Lognormal(µzu,σ2),
where CACEs are specified as CACEnor = µ1c−µ0c, CACEexp = 1/λ1c−1/λ0c, CACEgam = α1c/λ −
α0c/λ , and CACElog = exp{µ1c+σ2/2}− exp{µ0c+σ2/2}, respectively.
Next, Theorem 1 will show the identifiability of the parameters of θ . The proof of Theorem 1 is
provided in Appendix A. Assumption 5 implies θ1n = θ0n and θ1a = θ0a, which can be simplified as
θn and θa, respectively.
Theorem 1. Under Assumptions 1 to 7, the vector η = (p1(θn)− p1(θa), p1(θ1c)− p1(θa), p1(θ0c)−
p1(θn), . . ., pK(θn)− pK(θa), pK(θ1c)− pK(θa), pK(θ0c)− pK(θn), log{c(θn)}−log{c(θa)}, log{c(θ1c)}−
log{c(θa)}, log{c(θ0c)}− log{c(θn)}) is identifiable. If there exists a one-to-one mapping from the
parameter set θ to the vector η , then θ is identifiable and so is CACE.
The one-to-one mapping condition seems complicated, but it is reasonable and holds for many
widely-used distributions, such as homoskedastic normal distributions, exponential distributions, etc.
We will verify the one-to-one mapping condition for normal and exponential distributions in Appendix
C and Appendix D. Other distributions such as heteroskedastic normal distributions, Gamma distribu-
tions and lognormal distributions can be verified similarly. However, counterexamples do exist, and
we provide one in Appendix A.
3.2 TSMLE of CACE
Because we do not specify a parametric form on the missing data mechanism ρ(y), the joint distri-
bution of (Z,U,D,Y,R) is not specified completely. Thus the MLEs of parameters are hard to obtain,
since the likelihood depends on the infinite dimensional parameter ρ(y) as shown in Appendix B. In
this subsection, we propose a two-step likelihood method to estimate parameters, which can be viewed
as an example of the Two-Step Maximum Likelihood studied by Murphy and Topel (2002).
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In the first step, a consistent estimator for α = (ξ ,ωa,ωn) can be obtained by MLE using the data
{(Zi,Di) : i = 1, ...,N}. Let N denote the sample size, N1 = #{i : Zi = 1}, N0 = #{i : Zi = 0} and
nzd = #{i : Zi = z,Di = d} for z = 0,1 and d = 0,1. Then the log likelihood function for α is
l1(α) =N1 logξ +N0 log(1−ξ )+n11 log(1−ωn)+n10 log(ωn)+n01 log(ωa)+n00 log(1−ωa). (4)
The MLE for α is αˆ = (ξˆ , ωˆn, ωˆa) = (N1/N,n10/N1,n01/N0), equivalent to the moment estimator.
In the second step, we propose a conditional likelihood method to estimate the parameter set
θ , which is based on the conditional probability of (Z,D) given Y and R = 1. Here the proposed
conditional likelihood function does not depend on the nuisance parameter ρ(y), based on the fact that
the following equations (5) to (7) do not depend on ρ(y):
log
{
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ
}
= log
{
P(U = n) f (y | Z = 1,U = n)
P(U = a) f (y | Z = 0,U = a)
}
=
K
∑
k=1
{pk(θn)− pk(θa)}Tk(y)+ log
{
ωnc(θn)
ωac(θa)
}
, (5)
log
{
P(Z = 0,D = 0 | Y = y,R = 1)ξ
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ ) −1
}
= log
{
P(U = n) f (y | Z = 1,U = n)+P(U = c) f (y | Z = 0,U = c)
P(U = n) f (y | Z = 1,U = n) −1
}
= log
{
P(U = c) f (y | Z = 0,U = c)
P(U = n) f (y | Z = 1,U = n)
}
=
K
∑
k=1
{pk(θ0c)− pk(θn)}Tk(y)+ log
{
ωcc(θ0c)
ωac(θn)
}
, (6)
log
{
P(Z = 1,D = 1 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ −1
}
= log
{
P(U = a) f (y | Z = 1,U = a)+P(U = c) f (y | Z = 1,U = c)
P(U = a) f (y | Z = 0,U = a) −1
}
= log
{
P(U = c) f (y | Z = 1,U = c)
P(U = a) f (y | Z = 0,U = a)
}
=
K
∑
k=1
{pk(θ1c)− pk(θa)}Tk(y)+ log
{
ωcc(θ1c)
ωac(θa)
}
. (7)
It is obvious that
1
∑
z=0
1
∑
d=0
P(Z = z,D = d | Y = y,R = 1) = 1. (8)
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The left hand sides of equations (5) to (7) consist of P(Z = z,D = d | Y = y,R = 1) and ξ , with
the latter identified from the first step. The right hand sides of equations (5) to (7) consist of the
parameters of interest. Therefore we can estimate θ through a likelihood method. Note the right hand
sides do not depend on ρ(y), so we do not need to specify the form of ρ(y). Let pzd(θ ,α;y) denote
P(Z = z,D = d | Y = y,R = 1). Since (Z,D) given (Y = y,R = 1) follows a multinomial distribution
with four categories, the conditional log-likelihood function of (Z,D) can be written as
l2(θ ,α) =
N
∑
i=1
1
∑
z=0
1
∑
d=0
I(Zi = z,Di = d,Ri = 1) log pzd(θ ,α;yi). (9)
From the proof of Theorem 1, the parameter θ can be identified from the second likelihood func-
tion (9) after identifying α from the first likelihood function (4). Therefore, by maximizing l2(θ , αˆ)
over θ , we obtain the maximizer θˆ . In practice, we can use the bootstrap method to approximate the
sampling variance of the estimator of CACE.
4 Simulation Studies and Sensitivity Analysis
We report simulation studies and sensitivity analyses in order to evaluate the finite sample properties
of the estimating methods proposed in this paper. In Tables 2-4, the columns with labels “bias”,
“Std. dev.”, “95% CP” and “95% CI” represent the average bias, standard deviation, 95% coverage
proportion and average 95% confidence interval, respectively.
First, we generate the outcomes under the ODN missing data mechanism from homoskedastic nor-
mal distributions (denoted as “homo normal”), exponential distributions, Gamma distributions and
log-normal distributions, respectively. We set the number of simulations to be 10000, and choose
the sample sizes as 500,1000, 2000 and 4000, respectively. We show the joint distributions of
(Z,U,D,Y,R) in Table 1, and report the results in Table 2. The results have small biases and stan-
dard deviations, which decrease as the sample sizes become larger. And all the confidence intervals of
CACE have empirical coverage proportions very close to their nominal values.
10
Table 1: True parameters for simulation
homo normal Exponential Gamma Lognormal
Y (1)|U = c N(5,1) Exp(1/5) Gamma(5,1) Lognormal(0,1)
Y (0)|U = c N(4,1) Exp(1/4) Gamma(4,1) Lognormal(−1,1)
Y (z)|U = a N(6,1) Exp(1/6) Gamma(6,1) Lognormal(−1.5,1)
Y (z)|U = n N(3,1) Exp(1/3) Gamma(3,1) Lognormal(−0.5,1)
Z Bernoulli(0.5)
U ωc = ωn = ωa = 1/3
R|Y = y ρy = I(y≤ 2)×0.85+ I(y≥ 7)×0.8+ I(2 < y < 7)×0.9
Table 2: Results of simulation studies
true value N bias Std. dev. 95% CP 95% CI
CACEnor = 1.0 500 -0.0194 0.3395 0.9489 [0.3152, 1.6461]
1000 -0.0073 0.2343 0.9476 [0.5335, 1.4518]
2000 0.0022 0.1629 0.9500 [0.6828, 1.3215]
4000 -0.0019 0.1145 0.9504 [0.7736, 1.2225]
CACEexp = 1.0 500 0.0872 1.5910 0.9455 [-2.0312, 4.2056]
1000 0.0312 1.0309 0.9441 [-0.9893, 3.0517]
2000 0.0106 0.7091 0.9479 [-0.3793, 2.4004]
4000 0.0072 0.4891 0.9506 [0.0486, 1.9657]
CACEgam = 1.0 500 0.0830 1.6872 0.9915 [-2.2237, 4.3901]
1000 0.0284 0.5978 0.9625 [-0.1432, 2.2000]
2000 0.0108 0.3636 0.9493 [0.2981, 1.7235]
4000 0.0032 0.2530 0.9505 [0.5073, 1.4992]
CACElog = 1.0422 500 0.1156 0.7849 0.9617 [-0.3806, 2.6962]
1000 0.0599 0.4571 0.9494 [0.2061, 1.9981]
2000 0.0218 0.3093 0.9496 [0.4578, 1.6702]
4000 0.0106 0.2130 0.9469 [0.6353, 1.4702]
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Second, we report the results of comparison of our methods with the MLE proposed by O’Malley
and Normand (2005) (“LI” in Tables 3) under five different cases, which violate the homoskedastic
normal outcomes or the ODN assumption. We repeat our simulation 10000 times with sample sizes
of 4000 in each case. The results of five cases are shown in Table 3, named as “Heter”, “Unif”,“T”,
“DY” and “DYU”, respectively. The first case, “Heter” case, violates the homoskedastic normal out-
comes. Next two cases, “Unif” and “T”, violate the exponential family assumption. The last two
cases, “DY” and “DYU”, violate the ODN assumption. In the “Heter” case we generate data from
heteroskadastic normal outcomes. The data generating process is the same as “homo normal” ex-
cept that Y (1)|U = c ∼ N(5,0.25), Y (z)|U = a ∼ N(6,0.30) for z = 0,1. In the ‘Unif” case the data
is generated the same as “homo normal” except that the outcomes follow uniform distribution with
Y (1)|U = c ∼ U [2,8], Y (0)|U = c ∼ U [1,7], Y (z)|U = a ∼ U [3,9] and Y (z)|U = n ∼ U [1,5], re-
spectively. The data generating process in the “T” case is the same as “homo normal” except that
the outcomes follow t distributions with the same means as “homo normal” and degrees of freedom
4. In the “DY” case we generate data under the missing data mechanism depending on both D and
Y , and choose P(R = 1 | D,Y ) = 0.8− I(Y > 5)× 0.5+ I(D = 1)× 0.1− I(Y > 5)I(D = 0)× 0.1
with other conditional distributions the same as “homo normal”. In the “DYU” case we generate
data with the missing data mechanism depending on D, Y and U , and choose P(R = 1 | D,Y,U) =
(1+ exp{5+0.1D−Y −0.1U})−1, with other conditional distributions the same as “homo normal”
and U = 1,2,3 corresponding to U = c,n,a. From Table 3, we can see that the point estimator of
our method is generally robust to four kinds of violations of the assumptions. However, the results
are worse for “Unif” case, which has a large bias, low 95% coverage proportion and whose 95%
confidence interval does not cover the true value.
Finally, we compare our methods with the MLE proposed by O’Malley and Normand (2005) under
the LI missing data mechanism (“LI” in Table 4). We repeat our simulation 10000 times with sample
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Table 3: Comparison of the methods assuming ODN and LI under five cases which violate the ho-
moskedastic normal outcomes or the ODN assumption. (CACEtrue = 1.0)
Method Assump. bias Std. dev. 95% CP 95% CI
ODN Heter -0.0268 0.0772 0.9363 [0.8220, 1.1244]
Unif -0.3815 0.1865 0.4676 [0.2530, 0.9841]
T -0.0350 0.1730 0.9427 [0.6960, 1.3740]
DY 0.0201 0.1555 0.9465 [0.7154, 1.3249]
DYU -0.0852 0.1691 0.9242 [0.5834, 1.2462]
LI Heter -0.0277 0.0677 0.9300 [0.8395, 1.1051]
Unif -0.8521 0.2474 0.0695 [-0.3369, 0.6327]
T 0.2244 0.1225 0.5577 [0.9843, 1.4646]
DY -0.0288 0.0894 0.9370 [0.7959, 1.1465]
DYU -0.1267 0.1321 0.8426 [0.6144, 1.1322]
sizes of 4000 in each case. The data generating processes are the same as “homo normal”, but the
missing data mechanisms are LI. Denote γdu =P(R= 1 |D= d,U = u), and choose (γ1c,γ0c,γ0n,γ1a)=
(0.8,0.75,0.7,0.9), (0.9,0.7,0.8,0.7), (0.7,0.6,0.6,0.8) and (0.6,0.7,0.9,0.7) for “LI1” to “LI4” re-
spectively as shown in rows 1-4 and 5-8 of Table 4. Since the missing data mechanisms are LI, the
“LI” method exhibits very small biases. Although the assumptions required by the “ODN” methods
do not hold, the biases are not very large except for the missing mechanism LI4. The last case, LI4,
has the largest variability among the γzu’s and thus the largest bias for estimating the CACE, since the
missing data mechanism has the “strongest” dependence on D and U but not Y . Next we generate
data under the ODN assumption, and compare the methods under both ODN and LI assumptions. Let
ρ(y;δ ) = I(y≤ 2)× (0.9−δ )+ I(y≥ 7)× (0.9−2δ )+ I(2 < y < 7)×0.9 where 0 < δ < 0.9. As δ
increases, the relationship between Y and R becomes stronger. The data are generated from the same
joint distribution as “homo normal” except for different ρ(y;δ ). The results are shown in Figure 2.
The method under ODN missing data mechanism has small bias and promising coverage property ir-
respective of δ , but the method under LI missing data mechanism has larger bias and poorer coverage
property with larger δ .
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Table 4: Comparison of the methods assuming ODN and LI when LI holds. (CACEtrue = 1.0
Method bias Std. dev. 95% CP 95% CI
ODN LI1 -0.0291 0.1236 0.9438 [0.7287, 1.2132]
LI2 0.0976 0.1452 0.8961 [0.8130, 1.3823]
LI3 -0.0569 0.1371 0.9332 [0.6745, 1.2118]
LI4 -0.1961 0.1152 0.5966 [0.5781, 1.0297]
LI LI1 -0.0013 0.1123 0.9491 [0.7785, 1.2189]
LI2 -0.0010 0.1099 0.9504 [0.7836, 1.2145]
LI3 -0.0008 0.1262 0.9502 [0.7519, 1.2465]
LI4 -0.0015 0.1290 0.9505 [0.7456, 1.2515]
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Figure 2: Comparison of the methods assuming ODN and LI when ODN holds. (CACEtrue = 1.0)
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5 Application
We use the new methods proposed in this paper to re-analyze a psychiatric clinical trial. It is a double-
blinded randomized study comparing the relative effect of clozapine and haloperidol in adults with
refractory schizophrenia at fifteen Veterans Affairs medical centers. Clozapine is found to be more
efficacious than standard drugs in patients with refractory schizophrenia. Yet it is associated with
potentially fatal agranulocytosis. One objective for conducting this trial is to evaluate the clinical
effect of two antipsychotic medications. The dataset has been analysed in Rosenheck et al. (1997),
Levy et al. (2004), and O’Malley and Normand (2005). Some summary statistics of the data are
described in Table 5. More details about the trial can be found in Rosenheck et al. (1997) and O’Malley
and Normand (2005). In the treatment arm, 203 patients are randomized to clozapine; in the control
arm, 218 patients are randomized to haloperidol. The outcome of interest is the positive and negative
syndrome score (PANSS) with higher values indicating more severe symptoms. The baseline PANSS
is nearly balanced in both groups. Missing outcome patterns are obviously different in the clozapine
group (about 40/203≈ 0.20) than in the haloperidol group (about 59/218≈ 0.27). Hence it is possible
that outcomes are not missing at random. The primary reasons for dropout in the clozapine group are
side effects or non-drug-related reasons. The reasons for discontinuing haloperidol are lack of efficacy
or worsening of symptoms. Therefore, the missing mechanism may possibly depend on the missing
outcome, and we think that the ODN assumption may be more reasonable in this case.
The estimates of CACE by different methods are shown in Table 6. In Table 6, the “homo” and
“hetero” in parentheses after “ODN” correspond to the homoskedastic and heteroskedastic model
assumptions, respectively; and “LI” corresponds to the MLE proposed in O’Malley and Normand
(2005). The columns of Table 6 correspond to the methods, point estimates, standard errors, 95%
and 90% confidence intervals, respectively. The bootstrap method is used to compute standard errors
and confidence intervals for all methods. From Table 6, we can see that under the homoskedastic as-
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Table 5: Summary statistics of the data from the psychiatric clinical trial
Received treatment
Assigned treatment Clozapine (D = 1) Haloperidol (D = 0) Total
Clozapine (Z = 1)
Sample size 122 81 203
Missing sample size 0 40 40
Mean of the baseline PANSS 90.83 91.20 90.98
Haloperidol (Z = 0)
Sample size 57 161 218
Missing sample size 12 47 59
Mean of the Baseline PANSS 96.30 90.69 92.16
sumption subjects in the clozapine group had 5.00 lower symptom levels than those in the haloperidol
group, and under the heteroskedastic assumption it was 5.54. Both methods have similar conclusions
that clozapine is somewhat more effective than haloperidol for patients with refractory schizophrenia.
Both of the semiparametric methods give insignificant results since both 95% confidence intervals in-
clude zero. Our results are similar to O’Malley and Normand (2005) which also gave an insignificant
result. However, the results of the 90% confidence intervals are somewhat different: the result under
the ODN mechanism with the heteroskedastic assumption is significant, but the results from other two
models are not.
Assuming different missing data mechanisms such as LI, ODN and under other different assump-
tions on the outcome variable, we can find different point estimates and confidence intervals for CACE
using the data from the psychiatric clinical trial. When we have prior knowledge that the missing
mechanism depends only on the treatment received and the compliance status, the method under LI
missing mechanism will provide more credible conclusion. However, when we have prior knowl-
edge that the missing mechanism depends directly on the outcome, we recommend our methods under
the ODN missing data mechanism. The newly proposed methods can be used as alternatives for the
predominate methods assuming the LI missing mechanism in sensitivity analysis.
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Table 6: Estimates of CACE by different methods
Method Estimate S.E. 95% CI 90% CI
ODN(homo) -5.00 3.05 [-10.98, 0.98] [-10.02, 0.02]
ODN(hetero) -5.54 3.05 [-11.52, 0.44] [-10.56, -0.52]
LI -4.36 4.35 [-12.89, 4.17] [-11.52, 2.80]
6 Discussion
Randomization is a powerful tool to measure the relative causal effect of treatment versus control.
Some subjects in randomized trials, however, may fail to comply with the assigned treatments or
drop out before the final outcomes are measured. Noncompliance and missing data problems make
statistical causal inference difficult, because the causal effects are not identifiable without additional
assumptions. Under different assumptions about the missing data mechanisms of the outcomes, the
identifiability and estimation methods may be fundamentally different. Most previous studies (Fran-
gakis and Rubin, 1999; Barnard et al., 2003; O’Malley and Normand, 2005; Zhou and Li, 2006) rely
on the LI assumption in order to identify CACE, but the LI assumption may be not reasonable when
the missing data mechanism may depend on the outcome. Under the ODN missing data mechanism,
Chen et al. (2009) and Imai (2009) showed the identifiability and proposed the moment estimator and
the MLE of CACE for discrete outcomes. But there are no results for continuous outcomes under both
noncompliance and ODN missing data mechanism. As a generalization of Chen et al. (2009) and Imai
(2009), we study the semiparametric identifiability, and propose estimation methods for CACE with
continuous outcomes under the ODN missing data mechanism.
The ODN assumption allows the missing data mechanism to depend on the outcome. However, the
missing data processes in practical problems may be more complicated, and they may depend on other
variables such as Z, U and D. For example, a missing mechanism depending on both the compliance
status and the outcome may be reasonable in some real studies. Small and Cheng (2009) proposed a
saturated model for P(R = 1 | Z,U,Y ), and the models under LI and ODN are special cases of their
17
model. However, their model is generally not identifiable without restrictions on the parameters. It
is worthwhile to study the identifiability of CACE under all possible restrictions of P(R = 1 | Z,U,Y )
and perform sensitivity analysis for models lack of identifiability. We consider only cross-sectional
data in this paper, and generalizing our methods to longitudinal data is a future research topic.
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Appendices
Appendix A
Proof of Theorem 3.1. From equations (3.5) to (3.7), we can identify (p1(θn)− p1(θa), p1(θ1c)−
p1(θa), p1(θ0c)− p1(θn), . . ., pK(θn)− pK(θa), pK(θ1c)− pK(θa), pK(θ0c)− pK(θn), log{c(θn)}−
log{c(θa)}, log{c(θ1c)}− log{c(θa)}, log{c(θ0c)}− log{c(θn)}) using generalized linear models.
Therefore θ is identifiable because of the one-to-one mapping.
Counterexample for identifiability. Consider the following exponential family:
fzu(y) = f (y | Z = z,U = u) = c(θzu)h(y)exp
{
K
∑
k=1
θzu,kyk
}
.
The number of unknown parameters contained in θ is 4K, and the number of identifiable parameters
contained in η is 3(K+1). A necessary condition for the existence of a one-to-one mapping from θ
to η is 4K ≤ 3(K+1), or, equivalently, K ≤ 3. Therefore, when K > 3, a one-to-one mapping from θ
to η does not exist.
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Appendix B: Full likelihood for (α,θ ,ρ(y))
Define Mzd = #{i : Zi = z,Di = d,Ri = 0} for z = 0,1 and d = 0,1. Under the compound exclu-
sion restriction, we have f1n(y) = f0n(y) = fn(y) and f1a(y) = f0a(y) = fa(y). The full likelihood for
(α,θ ,ρ(y)) is
L(α,θ ,ρ(y))
∝ ξN1(1−ξ )N0(1−ωn)n11ωn10n ωn01a (1−ωa)n00
·
[
ωc
ωc+ωa
∫
{1−ρ(y)} f1c(y)dy+ ωaωc+ωa
∫
{1−ρ(y)} fa(y)dy
]M11 [∫
{1−ρ(y)} fn(y)dy
]M10
·
[∫
{1−ρ(y)} fa(y)dy
]M01 [ ωc
ωc+ωn
∫
{1−ρ(y)} f0c(y)dy+ ωnωc+ωn
∫
{1−ρ(y)} fn(y)dy
]M00
· ∏
i:Ri=1
ρ(Yi) · ∏
i:(Zi,Di,Ri)=(1,1,1)
{
ωc
ωc+ωa
f1c(Yi)+
ωa
ωc+ωa
fa(Yi)
}
∏
i:(Zi,Di,Ri)=(1,0,1)
fn(Yi)
· ∏
i:(Zi,Di,Ri)=(0,1,1)
fa(Yi) · ∏
i:(Zi,Di,Ri)=(0,0,1)
{
ωc
ωc+ωn
f0c(Yi)+
ωn
ωc+ωn
fn(Yi)
}
.
Appendix C: Verification of homoskedastic normal distribution in Subsection 3.2
For homoskedastic normal outcomes, equations (3.5) to (3.7) can be re-written as:
a1y+b1 = log
{
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ
}
=
µn−µa
σ2
y+
µ2a −µ2n
2σ2
+ log
{
ωn
ωa
}
,
a2y+b2 = log
{
P(Z = 0,D = 0 | Y = y,R = 1)ξ
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ ) −1
}
=
µ0c−µn
σ2
y+
µ2n −µ20c
2σ2
+ log
{
ωc
ωn
}
,
a3y+b3 = log
{
P(Z = 1,D = 1 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ −1
}
=
µ1c−µa
σ2
y+
µ2a −µ21c
2σ2
+ log
{
ωc
ωa
}
.
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Since ai and bi can be identified from generalized linear models, we can identify all the parameters
from the above equations and obtain the following results:
σ2 = 2
b1− log
{
ωn
ωa
}
a1
−
b2− log
{
ωc
ωn
}
a2
/(a1+a2),
= 2
b1− log
{
ωn
ωa
}
a1
−
b3− log
{
ωc
ωa
}
a3
/(a3−a1),
µ1c =
1
2
a3σ2−
b3− log
{
ωc
ωa
}
a3
,
µ0c =
1
2
a2σ2−
b2− log
{
ωc
ωn
}
a2
.
Therefore, we can identify CACE = µ1c−µ0c.
Appendix D: Verification of the exponential distribution in Subsection 3.2
For the exponentially distributed outcomes, equations (3.5) to (3.7) can be re-written as:
a1y+b1 = log
{
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ
}
= (λa−λn)y+ log
{
ωnλn
ωaλa
}
,
a2y+b2 = log
{
P(Z = 0,D = 0 | Y = y,R = 1)ξ
P(Z = 1,D = 0 | Y = y,R = 1)(1−ξ ) −1
}
= (λn−λ0c)y+ log
{
ωcλ0c
ωnλn
}
,
a3y+b3 = log
{
P(Z = 1,D = 1 | Y = y,R = 1)(1−ξ )
P(Z = 0,D = 1 | Y = y,R = 1)ξ −1
}
= (λa−λ1c)y+ log
{
ωcλ1c
ωaλa
}
.
Since ai and bi can be identified from generalized linear models, we can identify all the parameters
from the above equations and obtain the following results:
λ0c =
a1 exp{b1− log{ωn/ωa}}
1− exp{b1− log{ωn/ωa}} −a2,
λ1c =
a1
1− exp{b1− log{ωn/ωa}} −a3,
and CACE =
1
λ1c
− 1
λ0c
.
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